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ABSTRACT
Introduction: Patient-reported outcomes
(PROs) and satisfaction endpoints are increas-
ingly important in clinical trials and may be
associated with treatment adherence. In this
post hoc substudy from ROCKET AF, we
examined whether patient-reported satisfaction
was associated with study drug discontinuation.
Methods: ROCKET AF (n = 14,264) compared
rivaroxaban with warfarin for prevention of
stroke and systemic embolism in patients with
atrial fibrillation. We analyzed treatment satis-
faction scores: the Anti-Clot Treatment Scale
(ACTS) and Treatment Satisfaction Question-
naire for Medication version II (TSQM II). We
compared satisfaction with study drug between
the two treatment arms, and examined the
association between satisfaction and patient-
driven study drug discontinuation (stopping
study drug due to withdrawal of consent, non-
compliance, or loss to follow-up).
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Results: A total of 1577 (11%) patients partici-
pated in the Patient Satisfaction substudy; 1181
(8.3%) completed both the ACTS and TSQM II
4 weeks after starting study drug. Patients
receiving rivaroxaban did not experience sig-
nificant differences in satisfaction compared
with those receiving warfarin. During a median
follow-up of 1.6 years, 448 premature study
drug discontinuations occurred (213 rivaroxa-
ban group; 235 warfarin group), of which 116
(26%) were patient-driven (52 [24%] rivaroxa-
ban group; 64 [27%] warfarin group). No sig-
nificant differences were observed between
satisfaction level and rates of patient-driven
study drug discontinuation.
Conclusions: Study drug satisfaction did not
predict rate of study drug discontinuation. No
significant difference was observed between
satisfaction with warfarin and rivaroxaban, as
expected given the double-blind trial design.
Although these results are negative, the impor-
tance of PRO data will only increase, and these
analyses may inform future studies that explore
the relationship between drug-satisfaction
PROs, adherence, and clinical outcomes.
ClinicalTrials.gov: NCT00403767.
Funding: The ROCKET AF trial was funded by
Johnson & Johnson and Bayer.
Keywords: Anticoagulant; Atrial fibrillation;
Drug discontinuation; Patient-reported
outcomes; Patient satisfaction endpoints;
Rivaroxaban; Warfarin
INTRODUCTION
Patient-reported outcomes (PROs) used in clin-
ical practice and clinical research are health
outcomes reported directly by the patient,
without interpretation or confirmation from an
intermediary, such as a physician, nurse, or
study coordinator [1]. In 2004, the National
Institutes of Health roadmap for clinical
research identified the development of PROs as
a key priority, and multiple PRO tools have
been created and validated [2–14]. Guidelines
have been published recommending best prac-
tices for PRO use [15], and there have been calls
to comprehensively integrate PROs into car-
diovascular clinical trials [16]. PROs have been
used to compare patient satisfaction with war-
farin versus the direct oral anticoagulants
(DOACs), and have found higher satisfaction
with DOACs in patients with pulmonary
embolism (PE) [17], deep venous thrombosis
(DVT) [18], and atrial fibrillation (AF) [19–21].
However, these studies did not examine whe-
ther increased satisfaction predicts better med-
ication adherence. Nonadherence precludes
treatment efficacy and leads to worse outcomes
[22], and in clinical trials, study drug discon-
tinuation can undermine the scientific rigor of
the study. The objective of this substudy from
The Rivaroxaban Once Daily Oral Direct Factor
Xa Inhibition Compared with Vitamin K
Antagonism for Prevention of Stroke and
Embolism Trial in Atrial Fibrillation (ROCKET
AF) [23] was to determine if PROs assessing
study drug satisfaction are associated with study
drug discontinuation. We hypothesized that
patients who were more satisfied with the study
drug would be less likely to discontinue the
study drug.
METHODS
The design of ROCKET AF (NCT00403767) has
been previously described [23]. In brief,
ROCKET AF was a phase III, randomized, dou-
ble-blind, placebo-controlled, multicenter trial
of rivaroxaban compared with dose-adjusted
warfarin for the prevention of stroke and sys-
temic embolism in patients with nonvalvular
AF. A total of 14,264 patients were randomized
at 1178 centers in 45 countries. The protocol
was approved by ethics committees at partici-
pating sites, and all patients provided written
informed consent. Patients were included if
C. C. Nessel
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they had moderate-to-high risk for stroke.
Patients were randomized to rivaroxaban 20 mg
once daily, or 15 mg once daily in patients with
a creatinine clearance of 30–49 mL/min, or
dose-adjusted warfarin with a target interna-
tional normalized ratio of 2.0–3.0. It was
intended that patients would continue the
therapy throughout the duration of the trial,
unless discontinuation was clinically indicated,
or after meeting a primary endpoint in which
case discontinuation was mandated.
A subset of patients in ROCKET AF was given
two treatment satisfaction questionnaires: The
Anti-Clot Treatment Scale (ACTS) and the
Treatment Satisfaction Questionnaire for Medi-
cation version II (TSQM II). Both scales are val-
idated [24–27] and have been used extensively
in previous trials of anticoagulants [17–21, 28].
The subset of patients given the questionnaires
was selected at random from pre-selected sites
in the USA, Germany, and The Netherlands.
Sample size calculation was not performed, as
these analyses examining PROs and study-drug
discontinuation were not preplanned at the
start of ROCKET AF.
The ACTS is a 15-item patient-reported
instrument of satisfaction with anticoagulant
treatment and is summarized as two scales that
represent both negative and positive aspects of
anticoagulation treatment: ACTS Burdens (12
items), and ACTS Benefits (3 items). The ACTS is
an adaptation of the previously validated Duke
Anticoagulation Satisfaction Score [29]. For
each item, patient experience with anticoagu-
lation treatment is rated on a five-point Likert
scale from ‘‘Not at all’’ to ‘‘Extremely.’’ The 12
items of ACTS Burdens are reverse coded (scored
5–1), whereas the three items of ACTS Benefits
are coded normally (scored 1–5), so that higher
scores indicate greater patient satisfaction. Item
scores are summed across domains to give an
ACTS Burdens score ranging from 12 to 60 and
an ACTS Benefits score ranging from 3 to 15. A
patient must have data for all items of a scale for
the scale to be calculated. The ACTS was mea-
sured at 4, 8, 12, and 24 weeks after
randomization.
The TSQM II consists of ten items repre-
senting four scales: Effectiveness (2 items), Side
Effects (3 items), Convenience (3 items), and
Global Satisfaction (2 items). Experiences of
treatment satisfaction are rated on five-point
and seven-point Likert scales from ‘‘Extremely
dissatisfied’’ to ‘‘Extremely satisfied,’’ with scale
scores being converted to a score between 0 and
100, where higher scores indicate greater satis-
faction with treatment. A patient must have
data for all items of a scale in order for the scale
to be calculated, except for the Side Effects and
Convenience scales, for which up to one item
each could be missing. The TSQM II was mea-
sured at 4 and 24 weeks after randomization.
The current analysis includes data from both
questionnaires at 4 and 24 weeks, the time
points at which both surveys were carried out.
Our primary analysis examines survey responses
at 4 weeks, a time point that is far enough into
the course of therapy to gauge satisfaction, but
potentially early enough to intervene before
discontinuation occurs. In addition, we exam-
ined longer-term satisfaction using data at
24 weeks. Patients who were randomized and
received at least one dose of study drug were
included in the analysis if they had complete
data for both ACTS and TSQM II at 4 weeks and
were still on the assigned study drug at the
4-week visit.
Details about study drug administration were
collected rigorously including timing, duration,
and reason for interruptions or discontinuation
of study drug. Study drug discontinuation was
defined as a permanent discontinuation of ran-
domized study drug (i.e., stopping study drug
and not starting it again later). Temporary
interruptions of study drug, defined as stopping
study drug and starting it again later (for example
for a surgical procedure), were not included as
discontinuation outcomes. These discontinua-
tion definitions were used across all ROCKET AF
analyses that considered discontinuation in any
way [30]. Discontinuations were classified as
patient-driven discontinuation or non-patient-
driven discontinuation. Patient-driven discon-
tinuationwas defined as stopping study drug due
to any of the following reasons: withdrawal of
consent, noncompliance, or loss to follow-up.
Non-patient-driven discontinuationwas defined
as discontinuation for any other reason (e.g.,
adverse event, clinical efficacy endpoint reached,
investigator decision, protocol violation).
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Baseline characteristics and reasons for dis-
continuation are summarized using number
(percent) for categorical variables and median
(25th, 75th percentiles) for continuous vari-
ables. Scores for individual scales are summa-
rized using both median (25th, 75th
percentiles) and mean (standard deviation).
These scale summaries were carried out for both
4-week and 24-week data.
Patients were categorized as satisfied or not
satisfied in two ways, using 4-week data. For our
primary analysis, for each scale, we found the
minimum score reflecting satisfaction (e.g., an
answer of Satisfied, Very Satisfied, or Extremely
Satisfied for all score components; details in the
Supplemental Appendix). A patient was then
considered satisfied at 4 weeks if their score was
equal to or greater than this minimum score
(see Supplemental Appendix: Definition of
‘‘satisfied vs. ‘‘not satisfied’’ for each scale; min-
imum score for satisfaction for each subscale
was: ACTS Benefits[12, ACTS Burdens[ 42,
TSQM Effectiveness[ 66.67, Side Effects[100,
TSQM Convenience[ 66.7, TSQM Global Sat-
isfaction[66.7). For our sensitivity analysis, to
address any possible subjectivity in our defini-
tion for the primary analysis, we used the
median of each score distribution as the mini-
mum score cut-off to define satisfaction.
Rates of patient-driven discontinuation after
the 4-week survey are summarized for satisfac-
tion groups using events per 100 patient-years
and total events. To formally test this relation-
ship, we used Fine and Gray models, which are
semi-parametric proportional hazards models
that account for competing risks, in this case,
non-patient-driven discontinuation. Start time
for the models was the time of the 4-week
questionnaire. Models were adjusted for the
following variables found to be predictive of
patient-driven discontinuation in the full
ROCKET AF cohort (details of model develop-
ment are in the Supplemental Appendix): age,
sex, race, geographic region, prior stroke or
transient ischemic attack, history of depression,
prior vitamin K antagonist (VKA) use, and post-
randomization occurrence of bleeding or a
temporary interruption of study drug for a
procedure. Risk relationships are presented as
hazard ratios with 95% confidence intervals.
All analyses were conducted using SAS ver-
sion 9.4 or higher (SAS Institute Inc., Cary, NC).
RESULTS
Of 14,264 patients in ROCKET AF, 1577 partic-
ipated in the Patient Satisfaction substudy and
1181 remained on study drug at 4 weeks and
completed both the ACTS and TSQM II ques-
tionnaires 4 weeks after starting the study drug.
Of these patients, 572 (48.4%) had been ran-
domized to rivaroxaban, 609 (52.6%) to war-
farin. Baseline demographic characteristics were
similar in the two groups (Table 1). A total of
855 patients completed both the ACTS and
TSQM II at 24 weeks (72% of those who com-
pleted both questionnaires at 4 weeks), includ-
ing 398 (46.5% of those who completed both
questionnaires at 24 weeks) randomized to
rivaroxaban, and 457 (53.4% of those who
completed both questionnaires at 24 weeks)
randomized to warfarin.
Patient satisfaction measures at 4 weeks after
randomization, overall and by randomized
treatment, are presented in Table 2 and Fig. 1.
As expected, because of the double-blind
design, no differences were observed between
the randomized treatment arms in any scales.
In the longer term, satisfaction scores at
24 weeks were similar to those at 4 weeks (Sup-
plemental Table 1 and Supplemental Figure 1),
indicating that levels of satisfaction remained
consistent over time.
Over a median follow-up of 1.6 years, 448
early permanent study drug discontinuations
occurred; 116 (26%) of those were patient-dri-
ven (Table 3). Of those, 100 were due to with-
drawal of consent and 16 to noncompliance.
Among the 332 non-patient-driven discontinu-
ations, 210 were due to adverse events, 52 to
reaching a clinical efficacy endpoint, 44 to
investigator decision, and 26 to protocol viola-
tions. Discontinuation reasons for the entire
ROCKET AF cohort are in Supplemental Table 2.
The relationship between satisfaction and
discontinuation is presented in Table 4 and
Fig. 2. Although on three of the subscales (ACTS
Burdens, ACTS Benefits, and TSQM II Effective-
ness) there were numerically higher rates of
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Table 1 Baseline characteristics for patients participating in the patient satisfaction surveys
Variable All patients (N = 1181) Rivaroxaban (N = 572) Warfarin (N = 609)
Randomized to rivaroxaban 572 (48%)
Age (years) 75 (67, 79) 75 (67, 79) 75 (67, 79)
Female sex 398 (34%) 189 (33%) 209 (34%)
Geographic region
North America 776 (66%) 373 (65%) 403 (66%)
Western Europe 405 (34%) 199 (35%) 206 (34%)
Type of AF
Persistent 881 (75%) 423 (74%) 458 (75%)
Paroxysmal 286 (24%) 139 (24%) 147 (24%)
New onset 14 (1%) 10 (2%) 4 (1%)
CHADS2 score, mean (SD) 3.2 (1.0) 3.2 (1.0) 3.2 (1.0)
CHADS2 score
2 316 (27%) 146 (26%) 170 (28%)
3 471 (40%) 228 (40%) 243 (40%)
4 270 (23%) 137 (24%) 133 (22%)
5 96 (8%) 47 (8%) 49 (8%)
6 28 (2%) 14 (2%) 14 (2%)
Presenting characteristics
BMI (kg/m2) 29.8 (26.3, 33.8) 29.9 (26.6, 34.3) 29.8 (26.0, 33.5)
SBP (mmHg) 130 (120, 140) 130 (120, 140) 130 (120, 142)
DBP (mmHg) 78 (70, 85) 78 (70, 85) 78 (70, 85)
Heart rate (bpm) 72 (63, 82) 72 (63, 81) 72 (63, 82)
Creatinine clearancea (mL/min) 70 (54, 93) 72 (55, 94) 69 (53, 93)
Baseline comorbidities
Prior stroke/TIA/embolism 464 (39%) 225 (39%) 239 (39%)
Congestive HF 585 (50%) 286 (50%) 299 (49%)
Prior MI 248 (21%) 122 (21%) 126 (21%)
PAD 84 (7%) 34 (6%) 50 (8%)
Hypertension 1092 (92%) 531 (93%) 561 (92%)
Diabetes 540 (46%) 263 (46%) 277 (45%)
COPD 181 (15%) 94 (16%) 87 (14%)
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Table 2 ACTS and TSQM scores at 4 weeks after randomization, overall and by randomized treatment
Questionnaire/Scale All patients (N = 1181) Rivaroxaban (N = 572) Warfarin (N = 609) P value
ACTS
ACTS Burdens 57 (54, 59) 57 (54, 59) 57 (53, 59) 0.20
55.6 (5.0) 55.9 (4.7) 55.4 (5.2)
ACTS Benefits 12 (10, 14) 12 (10, 14) 12 (9, 14) 0.54
11.3 (3.1) 11.4 (3.0) 11.3 (3.2)
TSQM II
Effectiveness 67 (67, 83) 67 (67, 83) 67 (67, 83) 0.68
71.9 (19.1) 72.1 (19.1) 71.6 (19.1)
Side Effects 100 (92, 100) 100 (92, 100) 100 (92, 100) 0.48
93.2 (14.9) 92.8 (15.9) 93.6 (13.9)
Convenience 78 (67, 89) 78 (67, 89) 78 (67, 83) 0.26
77.2 (14.8) 77.7 (15.3) 76.8 (14.4)
Global Satisfaction 75 (67, 83) 75 (67, 83) 75 (67, 83) 0.24
75.4 (16.1) 75.9 (16.4) 74.9 (15.9)
For each scale, the top entry is median (25th, 75th percentiles) score and the bottom entry is mean (SD)
ACTS Anti-Clot Treatment Scale, TSQM II Treatment Satisfaction Questionnaire for Medication version II
Table 1 continued
Variable All patients (N = 1181) Rivaroxaban (N = 572) Warfarin (N = 609)
Medications
Prior VKA use 1020 (86%) 489 (85%) 531 (87%)
Prior chronic aspirin use 324 (27%) 158 (28%) 166 (27%)
ACE inhibitor/ARB at baseline 894 (76%) 444 (78%) 450 (74%)
Beta blocker at baseline 866 (73%) 410 (72%) 456 (75%)
Digitalis at baseline 443 (38%) 207 (36%) 236 (39%)
Diuretic at baseline 749 (63%) 366 (64%) 383 (63%)
Continuous variables are shown as median (25th, 75th percentiles) except where noted, and categorical variables as no. (%)
ACE angiotensin converting enzyme, AF atrial fibrillation, ARB angiotensin receptor blocker, BMI body mass index, bpm
beats per minute, CHADS2 congestive heart failure, hypertension, age C 75 years, diabetes mellitus, prior stroke or transient
ischemic attack or thromboembolism, COPD chronic obstructive pulmonary disease, DBP diastolic blood pressure, HF
heart failure, MI myocardial infarction, PAD peripheral artery disease, SBP systolic blood pressure, SD standard deviation,
TIA transient ischemic attack, VKA vitamin K antagonist
a Calculated using the Cockcroft–Gault equation
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discontinuations in the less satisfied group,
there were no statistically significant differences
in discontinuation rates between the more and
the less satisfied groups for any of the six satis-
faction subscales. The results of our sensitivity
analysis (which compared patients who were
above versus below median satisfaction) are
displayed in Supplemental Table 3. In this
analysis, too, there were no statistically
Fig. 1 Scales of patient satisfaction for the entire analysis cohort and by randomized treatment at 4 weeks after
randomization
Table 3 Reasons for early permanent study drug discontinuation in the analysis cohort
All patients (N = 1181) Rivaroxaban (N = 572) Warfarin (N = 609)
Discontinued study drug early 448 (37.9%) 213 (37.2%) 235 (38.6%)
Reason for discontinuation (% among discontinuing patients)
Patient-driven discontinuation 116 (25.9%) 52 (24.4%) 64 (27.2%)
Consent withdrawn 100 (22.3%) 46 (21.6%) 54 (23.0%)
Noncompliant with study medication 16 (3.6%) 6 (2.8%) 10 (4.3%)
Lost to follow-up 0 0 0
Non-patient-driven discontinuation 332 (74.1%) 161 (75.6%) 171 (72.8%)
Adverse event 210 (46.9%) 109 (51.2%) 101 (43.0%)
Clinical efficacy endpoint reached 52 (11.6%) 24 (11.3%) 28 (11.9%)
Investigator decision 44 (9.8%) 19 (8.9%) 25 (10.6%)
Protocol violation 26 (5.8%) 9 (4.2%) 17 (7.2%)
Data presented as no. (%)
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significant differences in discontinuation rates
between more and less satisfied patients.
DISCUSSION
In this substudy of anticoagulation-related
quality of life from the ROCKET AF trial,
patients with AF who were randomly assigned
in a double-blind fashion to rivaroxaban or
warfarin reported no difference in satisfaction
with study drug at 4 versus 24 weeks after
enrollment. As expected given the double-blind
trial design, similar satisfaction between
patients randomized to rivaroxaban versus
warfarin was observed. However, in contrast to
our hypothesis, we found no association
between anticoagulation satisfaction and
patient-driven study drug discontinuation.
Table 4 Association of patient satisfaction scales at 4 weeks with subsequent early study drug discontinuation
Questionnaire/Scale Cut-offa Not satisfiedb Satisfiedb HR (95% CI)c Not
satisfied vs. satisfied
P valuec
ACTS
Burdens
N 42 29 1152
Events/100 pt-years (total events) 6.89 (4) 5.41 (112) 1.44 (0.44–3.46) 0.50
Benefits
N 12 462 719
Events/100 pt-years (total events) 6.02 (51) 5.07 (65) 1.18 (0.81–1.71) 0.38
TSQM II
Effectiveness
N 67 195 986
Events/100 pt-years (total events) 7.00 (23) 5.16 (93) 1.23 (0.76–1.91) 0.38
Side Effects
N 100 326 855
Events/100 pt-years (total events) 5.55 (31) 5.41 (85) 0.99 (0.64–1.48) 0.95
Convenience
N 67 98 1083
Events/100 pt-years (total events) 4.61 (8) 5.52 (108) 0.77 (0.34–1.48) 0.48
Global Satisfaction
N 67 149 1032
Events/100 pt-years (total events) 5.32 (14) 5.47 (102) 0.95 (0.52–1.61) 0.86
ACTS Anti-Clot Treatment Scale, CI confidence interval, HR hazard ratio, TSQM II Treatment Satisfaction Questionnaire
for Medication version II
a Satisfaction is defined as a score at or above the cut-off
b Groups are defined using ‘‘satisfied’’ or ‘‘not satisfied’’ survey answers (primary analysis; see Methods)
c Hazard ratio and P value for discontinuation are from adjusted model
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As patient-centered care assumes a more
prominent role in treatment guidelines, the
need to systematically integrate PROs in car-
diovascular research has been emphasized
[2, 15, 16]. These results build on previous
studies of patient satisfaction with anticoagu-
lation. Earlier work has shown that some
patients have lower perceived quality of life
with warfarin [31, 32], validated PROs measur-
ing satisfaction with warfarin and the DOACs
[24–27], and suggested that patients have
higher satisfaction with rivaroxaban versus
warfarin across a number of indications [17–21].
Furthermore, studies have demonstrated low
rates of drug adherence, both in clinical trials
and in practice [33–38]. This study builds on
these two lines of research by examining whe-
ther PROs measuring satisfaction predict anti-
coagulant nonadherence.
Although we did not find any significant
relationship between study drug satisfaction
and discontinuation, we did observe some
nonsignificant associations. Higher satisfaction
on ACTS Burdens, ACTS Benefits, and TSQM II
Effectiveness were all nonsignificantly associ-
ated with lower discontinuation. This associa-
tion for the TSQM II Effectiveness subscale was
the largest and was present in both our primary
and secondary analyses. This may suggest that
patients would be willing to tolerate side effects
and inconvenience as long as they believe that a
drug is effective. Alternatively, it is possible that
these previously validated anticoagulation sat-
isfaction scales may not be as powerful predic-
tors in AF as they are in thromboembolic
disease. This observation may generate the
hypothesis that patients who have already had
DVT report higher satisfaction with anticoagu-
lants, and more generally that efficacy is per-
ceived as higher when a drug is used for
secondary versus primary prevention. Further
studies exploring this hypothesis and the
impact of PROs and drug discontinuation
Fig. 2 Patient-driven discontinuation rate (events/100 patient-years) by satisfaction levels at 4 weeks (primary analysis)
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should be studied in open-label trials with larger
sample sizes.
Participants assigned to rivaroxaban and
warfarin had similar satisfaction at 4 weeks and
24 weeks in this analysis likely because of the
double-blind study design that included
sophisticated sham INR testing in the rivaroxa-
ban group. These results support that the
blinding of the participants was preserved with
this approach [23]. Other studies of comparative
satisfaction used conditions more similar to
actual use, involving blood draws with warfarin
but not with rivaroxaban [17, 18]. The similar
satisfaction with warfarin and rivaroxaban on
every satisfaction subscale suggests that the
difference in satisfaction seen in other studies
may be attributable to the increased monitoring
with warfarin, rather than differences in drug
side effects or other non-monitoring-related
drug effects.
This study has several limitations. First, only
a subset of trial participants from North Amer-
ica and Western Europe participated in the
substudy, limiting the generalizability and sta-
tistical power. Second, there were a relatively
small number of discontinuation events, further
reducing statistical power. Third, given the
small sample and few endpoint events it was
not possible to evaluate the relationships
between satisfaction, adherence, and other
clinical outcomes.
CONCLUSIONS
In conclusion, in this substudy fromROCKETAF,
no statistically significant association between
self-reported study drug satisfaction and patient-
driven study drug discontinuationwas observed.
As expected in a double-blind trial, no significant
difference between satisfaction between the
rivaroxaban group and the warfarin group was
observed. Although these results were negative,
the importance of PRO data, even in the context
of blinded randomized controlled trials, will
undoubtedly continue to increase. ROCKET AF
successfully collected PRO data in a large clinical
trial, and these results may provide important
lessons for future clinical trials that collect and
monitor PROs to ascertain satisfaction, and
explore the relation of PROs to adherence and
other clinical outcomes.
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